PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.93% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-27.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2019-05-14
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-03-31 was 2.84%, a 14.06% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-09-30 was 2.35%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-06-30 was 2.25%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-03-31 was 2.49%, a 23.27% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 2.93%, a 17.67% increase from fiscal 2017.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.49%, a 23.27% increase from fiscal 2016.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 2.02%, a 16.87% decline from fiscal 2015.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.43%, a 10.99% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2018-12-31 | 2.93% 10-K · filed 2019-03-27 | |||
| 2018-09-30 | 2.93% 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | 2.93% 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 2.84% 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | 2.49% 10-K · filed 2019-03-27 | |||
| 2017-09-30 | 2.35% 10-Q · filed 2018-11-14 | 2.49% 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | 2.25% 10-Q · filed 2018-08-14 | 2.49% 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | 2.49% 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | 2.02% 10-K · filed 2018-03-26 | |||
| 2016-09-30 | 2.02% 10-Q/A · filed 2018-03-26 | |||
| 2016-06-30 | 2.02% 10-Q/A · filed 2018-03-26 | |||
| 2016-03-31 | 2.02% 10-Q/A · filed 2018-03-26 | |||
| 2015-12-31 | 2.43% 10-K · filed 2017-03-30 | |||
| 2015-09-30 | 2.43% 10-Q · filed 2016-11-10 | 2.43% 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | 1.83% 10-Q · filed 2016-08-11 | 1.83% 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | 1.51% 10-Q · filed 2016-05-12 | |||
| 2014-12-31 | 2.73% 10-K · filed 2016-03-30 | |||
| 2014-09-30 | 2.73% 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | 1.95% 10-Q · filed 2015-08-12 | 2.73% 10-Q · filed 2015-08-12 | ||
| 2013-12-31 | 2.19% 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |